## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.5% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($119.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 3)

**1. Seven States Join Abbott Infant Formula FCA Lawsuit, Alleging Years of Violations and Cover-Ups**
- Source: USA Herald | 20251203T185140 | Bearish | Relevance: 100%
- Seven states have joined a False Claims Act lawsuit against Abbott Laboratories, accusing the company of knowingly endangering infants and misrepresenting safety compliance related to federally funded nutrition programs. The 176-page intervention alleges that Abbott's Sturgis plant had endemic contamination and that the company concealed violations to secure formula contracts, affecting millions of vulnerable infants reliant on Medicaid and WIC programs. This legal escalation stems from the 2022 infant formula crisis and highlights the alleged misconduct's impact on public health and taxpayer-funded programs.

**2. Abbott Laboratories (NYSE: ABT) sees Vanguard report 10.05% beneficial stake**
- Source: Stock Titan | 20251203T110200 | Neutral | Relevance: 100%
- The Vanguard Group has disclosed an updated beneficial ownership stake of 10.05% in Abbott Laboratories (NYSE: ABT), holding 174,894,079 common shares. This Schedule 13G/A filing indicates that Vanguard, acting as an investment adviser, holds these securities in the ordinary course of business, not for influencing control of Abbott. The report details Vanguard's voting and dispositive powers, clarifying that clients receive dividends and sale proceeds.

**3. Seven deaths possibly linked to malfunctioning glucose monitors**
- Source: USA Today | 20251202T141100 | Bearish | Relevance: 100%
- Malfunctioning FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose trackers made by Abbott Diabetes Care have been linked to over 700 severe adverse events and seven potential deaths globally. The FDA issued an early alert regarding these sensors, which may provide incorrect low glucose readings leading to improper treatment decisions and serious health risks for diabetics. Abbott has identified and resolved the production issue and is offering replacements for impacted sensors.

**4. Abbott Moves to Acquire Exact Sciences**
- Source: Dark Daily | 20251201T111732 | Bullish | Relevance: 100%
- Abbott has announced a $21 billion deal to acquire Exact Sciences, aiming to expand its presence in the rapidly growing cancer diagnostics market and bring products like Cologuard and Oncotype DX under its umbrella. This merger is expected to accelerate early cancer detection, foster at-home testing, and significantly reshape the global diagnostics landscape. Industry observers believe the acquisition will transform cancer screening by integrating it more deeply into primary care services and expanding access globally.

**5. Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know**
- Source: Yahoo Finance Singapore | 20251203T140004 | Somewhat-Bullish | Relevance: 100%
- This article examines why Abbott Laboratories (ABT) is attracting investor attention, focusing on factors like earnings estimate revisions, projected revenue growth, and past financial performance. It highlights Abbott's Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term, and details its valuation based on the Zacks Value Style Score.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.1% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.2x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.1x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.3B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.1 |
| Current P/E | 24.2 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.6% to -3.5% (-4.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 43. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.51% (CS: 19) | Weak |
| RSI_14 | 42.6 | Neutral |
| MACD Histogram | -0.05 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.971x | Below |
| vs SMA200 | 0.957x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $125.29
- **Stop Loss:** $119.99 (4.2% risk)
- **Target:** $130.59 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 179
- **Position Value:** $22,426.91
- **Portfolio %:** 22.43%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*